Multiplex ligation-dependent probe amplification And Karyotyping: an Evaluation

ISRCTN ISRCTN47252164
DOI https://doi.org/10.1186/ISRCTN47252164
Secondary identifying numbers 80-007029-98-07-047
Submission date
22/01/2007
Registration date
22/01/2007
Last edited
03/06/2008
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Other
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Ms Elisabeth Boormans
Scientific

Onze Lieve Vrouwe Gasthuis (OLVG)
Department of Obstetrics and Gynaecology
P.O. Box 95500
Amsterdam
1090 HM
Netherlands

Phone +31 (0)20 599 3477
Email e.m.a.boormans@olvg.nl

Study information

Study designProspective study of two paired diagnostic tests.
Primary study designInterventional
Secondary study designMulti-centre
Study setting(s)Not specified
Study typeDiagnostic
Scientific title
Study acronymMAKE
Study objectivesThe present study will evaluate the hypothesised equivalent pre-clinical diagnostic accuracy of Multiplex Ligation-dependent Probe Amplification (MLPA) compared to karyotyping in a clinical setting.
Ethics approval(s)Approval received from the local ethics committee (Medisch Ethische Toetsings Commissie) on the 21st August 2006 (ref: WO 06.032).
Health condition(s) or problem(s) studiedTrisomy 13, Trisomy 21, Fetal aneuploidies, Trisomy 18, Sex chromosome abnormalities
InterventionIn each patient, amniotic fluid is assessed with MLPA (experimental diagnostic test) and Karyotyping (gold standard).

MPLA:
MLPA is a molecular genetic technique in prenatal diagnosis using amniotic fluid. In this study a commercially available kit, P095 is used (produced by MRC Holland and widely tested).

The MLPA-result is known in two to four days. To perform MLPA 2 - 4 ml of amniotic fluid is required. Such an amount is available since routinely 15 - 20 ml of amniotic fluid is obtained.

If there is too little amniotic fluid (less than 12 ml), MLPA will not be carried out in the study.

Karyotyping:
Karyotyping is carried out without any changes. The result is known in two to three weeks.
Intervention typeOther
Primary outcome measure1. Diagnostic accuracy
2. Technical performance (inconclusive or missing results)
3. Technical capacity
Secondary outcome measures1. Patient anxiety and distress
2. Cost-effectiveness
3. Unexpected findings
4. Patient preference
Overall study start date01/02/2007
Completion date01/01/2009

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexNot Specified
Target number of participants4500 paired MLPA-Karyotyping test results
Key inclusion criteria1. Amniocentesis is performed
2. The referral indication is advanced maternal age and/or increased risk after PreNatal Screening (PNS)
3. Aged more than or equal to 18 years
4. No language barriers
5. Informed consent is given
6. Singleton pregnancies
Key exclusion criteriaOther referral indications:
1. Parent(s) with chromosome aberration
2. Ultrasound abnormalities
3. Previous child with chromosome aberration
Date of first enrolment01/02/2007
Date of final enrolment01/01/2009

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Onze Lieve Vrouwe Gasthuis (OLVG)
Amsterdam
1090 HM
Netherlands

Sponsor information

Onze Lieve Vrouwe Gasthuis (OLVG) (The Netherlands)
Hospital/treatment centre

Department of Obstetrics and Gynaecology
P.O. Box 95500
Amsterdam
1090 HM
Netherlands

Website http://www.olvg.nl/
ROR logo "ROR" https://ror.org/01d02sf11

Funders

Funder type

Research organisation

Netherlands Organisation for Health Research and Development (ZonMw) (The Netherlands)
Private sector organisation / Other non-profit organizations
Alternative name(s)
Netherlands Organisation for Health Research and Development
Location
Netherlands

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article Protocol 20/05/2008 Yes No